C4A and systemic lupus erythematosus: Currently, the clinical indicators of SLE diagnosis or progression monitoring, such as anti-dsDNA antibody, urinary protein, serum creatinine clearance rate, complements C3 and C4, or renal biopsy (38–40), have obvious limitations and have failed to fulfill clinical needs.